<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00045149</url>
  </required_header>
  <id_info>
    <org_study_id>1588.00</org_study_id>
    <secondary_id>FHCRC-1588.00</secondary_id>
    <secondary_id>NCI-H02-0091</secondary_id>
    <secondary_id>CDR0000256451</secondary_id>
    <nct_id>NCT00045149</nct_id>
    <nct_alias>NCT00029432</nct_alias>
  </id_info>
  <brief_title>Biological Therapy in Treating Patients With Metastatic Melanoma</brief_title>
  <official_title>Phase I Study to Evaluate the Safety of Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen Specific T Cell Clones Targeting Cancer Testis Antigens for Patients With Metastatic Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Biological therapies such as cellular adoptive immunotherapy use different ways to&#xD;
      stimulate the immune system and stop cancer cells from growing. Treating a person's white&#xD;
      blood cells in the laboratory and then reinfusing them may cause a stronger immune response&#xD;
      and kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of biological therapy in treating patients&#xD;
      who have metastatic melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the safety and toxicity of cellular adoptive immunotherapy comprising&#xD;
           autologous CD8+ cytotoxic T-lymphocyte clones targeting cancer-testis antigens in&#xD;
           patients with metastatic melanoma.&#xD;
&#xD;
        -  Determine the duration of in vivo persistence of this therapy in these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Evaluate the antitumor effects of this therapy in these patients.&#xD;
&#xD;
      OUTLINE: Patients undergo leukapheresis to obtain peripheral blood mononuclear cells and then&#xD;
      CD8+ cytotoxic T-lymphocyte (CTL) clones are generated ex vivo. Patients receive cellular&#xD;
      adoptive immunotherapy comprising autologous CD8+ CTL clones targeting cancer testis antigens&#xD;
      IV over 30 minutes on day 1. Patients also receive interleukin-2 subcutaneously every 12&#xD;
      hours on days 1-14 of courses 2-4. Treatment repeats every 3 weeks for 4 courses in the&#xD;
      absence of disease progression or unacceptable toxicity. Patients who demonstrate a clinical&#xD;
      response after completion of the fourth course are eligible to receive additional T-cell&#xD;
      infusions.&#xD;
&#xD;
      Patients are followed for 9 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study within 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2002</start_date>
  <completion_date type="Actual">June 2005</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Melanoma (Skin)</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aldesleukin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>therapeutic tumor infiltrating lymphocytes</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed metastatic melanoma&#xD;
&#xD;
               -  Stage IV disease&#xD;
&#xD;
          -  HLA-A1, -A2, and -A3 positive&#xD;
&#xD;
          -  MAGE-1 or -3 positive by histology&#xD;
&#xD;
          -  Bidimensionally measurable disease by palpation on clinical examination, x-ray, or CT&#xD;
             scan&#xD;
&#xD;
          -  No CNS metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 to 75&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 80-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  More than 6 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin ≤ 1.6 mg/dL&#xD;
&#xD;
          -  SGOT ≤ 3 times upper limit of normal&#xD;
&#xD;
          -  PT ≤ 1.5 times control&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 2.0 mg/dL&#xD;
&#xD;
          -  Calcium ≤ 12 mg/dL&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No congestive heart failure&#xD;
&#xD;
          -  No clinically significant hypotension&#xD;
&#xD;
          -  No symptoms of coronary artery disease&#xD;
&#xD;
          -  No cardiac arrhythmias on electrocardiogram requiring drug therapy&#xD;
&#xD;
          -  Patients with prior cardiovascular disease or the presence of any of the above&#xD;
             abnormalities undergo a cardiac evaluation, which may include a stress test and/or&#xD;
             echocardiogram&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No clinically significant pulmonary dysfunction by medical history or physical&#xD;
             examination&#xD;
&#xD;
          -  FEV_1 ≥ 60% of normal&#xD;
&#xD;
          -  DLCO ≥ 55% (corrected for hemoglobin)&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No retinitis or choroiditis&#xD;
&#xD;
          -  No active infections or oral temperature greater than 38.2 degrees Celsius within the&#xD;
             past 72 hours&#xD;
&#xD;
          -  No systemic infection requiring chronic maintenance or suppressive therapy&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No other concurrent immunotherapy (e.g., other interleukins, interferons, melanoma&#xD;
             vaccines, intravenous immunoglobulin, or expanded polyclonal tumor-infiltrating&#xD;
             lymphocytes or lymphokine-activated killer cell therapy)&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  At least 3 weeks since prior standard or experimental chemotherapy&#xD;
&#xD;
          -  1-2 courses of prior cytoreductive chemotherapy for bulky disease allowed&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  No concurrent systemic steroids (except for toxicity management)&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  At least 3 weeks since prior radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  At least 3 weeks since prior immunosuppressive therapy&#xD;
&#xD;
          -  No concurrent pentoxifylline&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cassian Yee, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Fred Hutchinson Cancer Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2010</verification_date>
  <study_first_submitted>September 6, 2002</study_first_submitted>
  <study_first_submitted_qc>May 27, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2003</study_first_posted>
  <last_update_submitted>May 5, 2010</last_update_submitted>
  <last_update_submitted_qc>May 5, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 7, 2010</last_update_posted>
  <keyword>recurrent melanoma</keyword>
  <keyword>stage IV melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aldesleukin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

